Transgene (TNG)

Business description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

Restructuring to focus on R&D

Flash note | Pharmaceutical & healthcare | 30/06/2015

Transgene has announced restructuring plans to focus the business on research and development. This will result in closure of the pharmaceutical development and bio-manufacturing business (c €1.7m revenue in 2014) but should lead to long-term cost savings. We have placed our valuation and financials under review pending details on the likely impact of the restructuring and updated clinical development plans.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€184.1m
Last close€2.965
High / Low (52 weeks)€3.6 / €2.5
Stock market listingEU
Forecast net debt (€m)39.8
Forecast gearing ratio (%)1637
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(4.2)(5.1)(12)
Relative *(7.8)(10.3)(17.5)

* % Relative to local index

Company news

Transgene

Thu, 08 Jun 2017 16:02:29 GMT

Transgene

Mon, 13 Mar 2017 18:22:30 GMT

Transgene

Fri, 10 Nov 2017 06:56:15 GMT

Transgene

Wed, 04 Apr 2018 16:03:29 GMT

Transgene

Thu, 15 Mar 2018 09:46:19 GMT